News from orexo A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Oct 24, 2018, 02:49 ET Orexo Appoints Joseph DeFeo as New CFO

Orexo AB announces today that the company appoints Joseph DeFeo as the company's new Chief Financial Officer (CFO) from November 1, 2018. Joseph...

Oct 08, 2018, 11:58 ET Orexo Appoints Nomination Committee and Publishes Financial Calendar 2018/2019

Prior to the Annual General Meeting 2019, Orexo appoints a Nomination Committee which represents approximately 45 percent of the number of shares and ...

Oct 01, 2018, 02:20 ET Orexo Internalizes Contract Field Force in the US to Further Strengthen the Commercial Organization

Orexo AB (publ) today announces that the field representatives in the contracted field force have been offered direct employment with Orexo US Inc....

Sep 10, 2018, 15:14 ET Orexo Wins Appeal Against Actavis on Zubsolv Patent in the US

Orexo AB (publ.) today announces that the US Court of Appeals for the Federal Circuit found Orexo's long term Zubsolv patent US 8,940,330 to be...

Jul 11, 2018, 02:43 ET Orexo: Interim Report Q2 2018

Q2 2018 highlights Total net revenues of SEK 199.7 million (159.1), up 25.5 percent from Q2 previous year Zubsolv US net revenue of SEK 158.4 million ...

Jun 29, 2018, 12:08 ET Number of Shares and Votes in Orexo

The number of shares and votes in Orexo AB has changed as a result of the issue and repurchase of 325,000 class C shares as announced on June 15,...

May 31, 2018, 02:56 ET Orexo´s CFO Resigns and Will Leave the Company in November 2018

Orexo AB today announces that Henrik Juuel has notified the company of his resignation after working for five years as the company´s Chief Financial...

Apr 26, 2018, 02:19 ET Orexo - Interim Report Q1 2018

Q1 2018 highlights Total net revenues of SEK 139.7 million, up 9.7 percent from Q1 previous year Zubsolv US net revenue of SEK 131.1 million, up 14.9 ...

Mar 22, 2018, 03:30 ET Orexo Publishes the Annual Report for 2017

Orexo's Annual Report for the 2017 fiscal year has been published and can be downloaded on the company's website, www.orexo.com (investors/reports,...

Mar 08, 2018, 08:12 ET Notice of Annual General Meeting of Orexo

The shareholders in Orexo AB (publ) are summoned to the annual general meeting, to be held on Thursday 12 April 2018, at 4.00 pm in Orexo's...

Jan 31, 2018, 12:24 ET Number of Shares and Votes in Orexo

The number of shares and votes in Orexo AB has changed as a result of the exercise of warrants in connection with the company's incentive programs....

Dec 12, 2017, 01:49 ET Orexo Discloses More Information About the Improved Market Access Position for Zubsolv® US in 2018

Orexo AB today announces specific information about the improved market access position for Zubsolv (buprenorphine and naloxone) sublingual tablet...

Nov 30, 2017, 01:38 ET Orexo Publishes Prospectus and Applies for Listing of Bonds on Nasdaq Stockholm

On 31 October 2017,Orexo AB (publ) (the "Company") announced that the Company successfully had issued a four-year senior unsecured bond loan in an...

Nov 22, 2017, 01:49 ET Orexo Completes Early Redemption of Existing Bond Loan

Orexo AB (publ.) (the "Company") today announces that the Company, in accordance with Orexo's press release on 31 October 2017, has completed the...

Nov 20, 2017, 08:02 ET Zubsolv® Receives Authorization for Treatment of Opioid Dependence in Europe

Orexo AB (publ.) today announce that the European Medicines Agency (EMA) has granted a Marketing Authorization (MA) for Zubsolv (buprenorphine and...

Oct 31, 2017, 04:00 ET Orexo Issues Bonds of SEK 325 Million and Confirms Fulfilment of Condition Under Notice of Early Redemption

Orexo AB (publ.) (the "Company") has issued a four-year senior unsecured bond loan in an amount of SEK 325 million, within a framework amount of SEK...

Oct 27, 2017, 03:37 ET Orexo Announces Conditional Total Redemption of its Senior Unsecured Bonds

Orexo AB (publ.) (the "Company") announces today that the Company will issue a notice of conditional early total redemption (the "Notice") of its...

Oct 19, 2017, 02:16 ET Orexo Interim Report Q3 2017

Financial overview Q3 2017 Total net revenues SEK 166.2 million (181.9) Zubsolv® US net revenue SEK 121.1 million (142.4) EBIT SEK 40.9 million...

Oct 03, 2017, 11:56 ET Orexo Appoints Nomination Committee and Publishes Financial Calendar 2017/2018

Prior to the Annual General Meeting 2018, Orexo appoints a Nomination Committee which represents approximately 45 percent of the number of shares and ...

Oct 02, 2017, 02:19 ET Orexo Signs Asset Purchase Agreement With Gesynta Pharma AB for OX-MPI

Orexo AB (publ.) today announced that Orexo has signed an asset purchase agreement with Gesynta Pharma AB – a recently formed research company...

Sep 15, 2017, 08:05 ET CHMP Positive Opinion for Opioid Dependence Treatment With Zubsolv® (buprenorphine and naloxone) in Europe

Mundipharma and Orexo AB (publ.) today announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) ...

Aug 02, 2017, 03:27 ET Orexo: Zubsolv® Gains Preferred Position on CVS Caremark 2018 Formulary

Orexo AB announced today changes to Zubsolv (buprenorphine and naloxone) sublingual tablet (CIII) managed care formulary position with CVS Caremark...

Jul 11, 2017, 02:16 ET Orexo Interim Report Q2 2017

Financial overview Q2 2017 Total net revenues SEK 159.1 million (188.2) Zubsolv® US net revenue SEK 124.1 million (112.8) EBIT SEK 9.8 million (12.1) ...

Jun 30, 2017, 12:10 ET Number of Shares and Votes in Orexo

UPPSALA, Sweden, June 30, 2017 The number of shares and votes in Orexo AB has changed as a result of the issue and repurchase of class C shares as...

Jun 16, 2017, 11:53 ET Issue and Repurchase of Class C Shares

Orexo AB (publ.) announces that the company has resolved to issue and immediately thereafter repurchase 230,000 class C shares. The shares are issued ...